Welcome to our dedicated page for Virpax Pharmaceuticals news (Ticker: VRPX), a resource for investors and traders seeking the latest updates and insights on Virpax Pharmaceuticals stock.
Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) is a preclinical-stage pharmaceutical company focused on non-opioid, non-addictive pain management and central nervous system (CNS) disorders, using novel drug delivery technologies. The Virpax news feed on Stock Titan highlights company announcements that describe progress across its prescription and nonprescription product candidates and capital markets activity.
News items commonly cover Virpax’s pipeline developments, such as preclinical dose range finding studies and animal model data for Probudur™, its long-acting liposomal bupivacaine formulation for post-operative pain. Releases also discuss updates on Envelta™ (NES100), an intranasal molecular envelope enkephalin formulation for acute and chronic pain, and NobrXiol™, an intranasal cannabidiol (CBD) candidate for rare pediatric epilepsy that uses Molecular Envelope Technology (MET) to target delivery to the brain.
Investors can follow announcements about Virpax’s collaborations and CRADAs with organizations such as the National Institutes of Health, the Department of Defense, and the U.S. Army Institute of Surgical Research, which has evaluated Probudur in combat care-related pain models. The news stream also includes updates on MET-related studies conducted by partners like Nanomerics, including human safety data for MET-based formulations.
In addition, Virpax issues news regarding financing transactions, including public offerings of common stock and pre-funded warrants, and corporate actions such as reverse stock splits intended to support continued listing on the Nasdaq Capital Market. The company also reports on exploratory work using MET or similar technology for intranasal mRNA COVID vaccine delivery and on efforts to seek partners for nonprescription candidates such as AnQlar and Epoladerm.
By monitoring this page, readers can review Virpax’s official press releases on its research progress, regulatory interactions, collaborations, and capital markets events in one place.
Virpax Pharmaceuticals (NASDAQ: VRPX) has announced a 1-for-25 reverse stock split effective March 20, 2025. The company's common stock will begin trading on a split-adjusted basis on March 21, 2025, maintaining its VRPX symbol on the Nasdaq Capital Market.
The reverse split will reduce outstanding shares from approximately 31,062,581 to 1,242,504. Stockholder ownership percentages will remain unchanged except for fractional shares. The split will proportionally adjust the number of shares issuable through equity awards and warrants, including their exercise prices.
This strategic move aims to achieve compliance with Nasdaq's minimum bid price requirement of $1.00 per share and attract a broader investor base. Stockholders approved the split at a January 15, 2025 special meeting, granting the Board discretion for a ratio between 1-for-2 and 1-for-240.
Virpax Pharmaceuticals (NASDAQ: VRPX) has announced positive results from a beagle dog dose range finding (DRF) study for Probudur, their long-acting liposomal bupivacaine formulation designed for post-surgical pain management.
The study demonstrated that beagle dogs showed positive tolerance to Probudur with no adverse effects, with doses up to 90 mg/kg being well-tolerated. This marks a significant step toward their Investigational New Drug (IND) application.
Probudur, a local anesthetic that blocks pain signals by binding to sodium channels, has shown promising results in preclinical studies:
- Pain control lasting at least 96 hours
- Analgesia for up to 5 days in rat incisional models
- Slow bupivacaine release lasting up to 6 days in vitro
Virpax Pharmaceuticals (VRPX) is exploring the use of Molecular Envelope Technology (MET) or similar technology to develop an intranasal mRNA COVID vaccine. The company aims to create a needle-free delivery system similar to FluMist, utilizing non-lipid polymer technology that may offer improved safety and reduced side effects compared to current lipid-based delivery systems.
The company currently employs MET in two other products: Envelta (NES100), an enkephalin-based drug product using nanotechnology for enhanced brain delivery, and NobrXiol (VRP324), a cannabidiol treatment for epilepsy that uses MET to cross the blood-brain barrier through nasal delivery. NobrXiol has received pre-IND guidance from the FDA.
Virpax Pharmaceuticals (NASDAQ: VRPX) announced that its NES100 dose range finding toxicity study will be presented at The Society of Toxicology 64th annual meeting in Orlando, FL, March 16-20th. The company has received an extension of its research agreement with the National Center for Advancing Translational Sciences (NCATS) for NES100's development.
NES100 is an intranasal enkephalin-based peptide designed for acute and chronic non-cancer pain management. The product utilizes nanotechnology delivery through the upper nasal cavity, bypassing the blood-brain barrier via olfactory neurons. The Molecular Envelope Technology (MET) helps deliver the drug directly to the brain, targeting delta opioid receptors for pain suppression.
Notably, animal studies have shown analgesic effects without typical opioid-related complications such as tolerance, withdrawal, respiratory depression, euphoria, or addiction.
Virpax Pharmaceuticals (VRPX) announced positive results from Nanomerics' human study of Molecular Envelope Technology (MET), showing no moderate to severe adverse events. MET is a key component in Virpax's two main products: Envelta and NobrXiol.
The SUNLIGHT trial, a Phase I study conducted with 10 volunteers over 28 days, tested MET-powered eye drops with twice-daily administration. The trial demonstrated safety and tolerability with no significant adverse effects or changes in safety assessments.
Envelta, developed in partnership with the National Center for Advancing Translational Sciences, uses MET to deliver enkephalin for pain management without opioid tolerance risks. NobrXiol utilizes MET to deliver cannabidiol across the blood-brain barrier for epilepsy management in children and adults.
Virpax Pharmaceuticals (NASDAQ: VRPX) has announced positive results from a comprehensive study of Probudur™ conducted by the U.S. Army Institute of Surgical Research (USAISR). The study, following an initial pilot study under a Cooperative Research and Development Agreement (CRADA), evaluated Probudur's effectiveness in reducing pain behaviors in a rat model of incisional pain.
The study compared Probudur with free bupivacaine and EXPAREL®, testing various concentrations of Probudur injected around incision sites. Results showed that Probudur doses effectively reduced incision-induced pain behaviors. In preclinical studies, Probudur demonstrated long-duration pain control lasting at least 96 hours, with rat models showing analgesia for up to five days and in vitro studies showing slow bupivacaine release for up to six days.
Virpax Pharmaceuticals (NASDAQ: VRPX), a company focused on developing non-addictive products for pain management, PTSD, CNS disorders, and anti-viral barrier indications, announced that Matthew Barnes, senior director of portfolio management, will present at the Outsourcing in Clinical Trials Conference. The OCT series is a prominent conference bringing together over 1,000 industry leaders annually to discuss clinical trial optimization and cost management.
Additionally, the company announced that Dr. Sheila Mathias (Chief Scientific Officer) and Matthew Barnes have published two articles in the DIA Global Forum and one article in the OCT Handbook 2025.
Virpax Pharmaceuticals (NASDAQ: VRPX) has announced the closing of a $6.0 million public offering of common stock and pre-funded warrants. The offering price was set at $0.20 per share (minus $0.00001 per pre-funded warrant). The proceeds will be used to fund clinical trial development for their product candidate Probudur, marketing and advertising services for financial community communications, working capital, and other general corporate purposes.
Spartan Capital Securities, served as the exclusive placement agent for the offering. The securities were offered through a registration statement on Form S-1, which was filed with the SEC on July 29, 2024, amended on January 15 and 17, 2025, and declared effective on January 27, 2025.
Virpax Pharmaceuticals (Nasdaq: VRPX) has announced the pricing of a $6 million public offering of common stock and pre-funded warrants. The offering includes shares priced at $0.20 and pre-funded warrants at $0.19999 per share.
The proceeds will be used to fund ongoing development activities for the clinical trial of Probudur, marketing and advertising services for financial community communications, working capital, and general corporate purposes. Spartan Capital Securities is serving as the exclusive placement agent.
The offering is expected to close on January 29, 2025, subject to customary conditions, and is being conducted under the Company's Form S-1 registration statement, which was declared effective by the SEC on January 27, 2025.
Virpax Pharmaceuticals (NASDAQ: VRPX) announced positive results from a minipig Dose Range Finding study for Probudur, their long-acting liposomal bupivacaine formulation for pain management. The study evaluated Probudur's tolerance in an incisional wound healing model, with all minipigs showing positive tolerance and no adverse effects. Preclinical studies demonstrated pain control lasting up to 96 hours, with rat models showing analgesia for up to five days and in vitro studies showing bupivacaine release for up to six days. Probudur aims to provide immediate and extended pain relief while reducing or eliminating post-surgical opioid needs.
FAQ
What is the current stock price of Virpax Pharmaceuticals (VRPX)?
What is the market cap of Virpax Pharmaceuticals (VRPX)?
